Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Prolonging the Reduction of Nicotine Self-Administration in Rats by Coadministering Chronic Nicotine With Amitifadine, a Triple Monoamine Reuptake Inhibitor With CYP2B6 Inhibitory Actions.

Levin ED, Wells C, Slade S, Lee M, McKinney AA, Rose JE, Rezvani AH.

Nicotine Tob Res. 2019 Apr 11. pii: ntz054. doi: 10.1093/ntr/ntz054. [Epub ahead of print]

PMID:
31187118
2.

Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats.

Levin ED, Wells C, Johnson JE, Rezvani AH, Bymaster FP, Rose JE.

Eur J Pharmacol. 2015 Oct 5;764:30-7. doi: 10.1016/j.ejphar.2015.06.041. Epub 2015 Jun 20.

3.

Reduction of nicotine self-administration by chronic nicotine infusion with H1 histamine blockade in female rats.

Levin ED, Hall BJ, Chattopadhyay A, Slade S, Wells C, Rezvani AH, Rose JE.

Psychopharmacology (Berl). 2016 Aug;233(15-16):3009-15. doi: 10.1007/s00213-016-4347-1. Epub 2016 Jun 18.

4.

Persistent attenuation of nicotine self-administration in rats by co-administration of chronic nicotine infusion with the dopamine D1 receptor antagonist SCH-23390 or the serotonin 5-HT2C agonist lorcaserin.

DiPalma D, Rezvani AH, Willette B, Wells C, Slade S, Hall BJ, Levin ED.

Pharmacol Biochem Behav. 2019 Jan;176:16-22. doi: 10.1016/j.pbb.2018.11.002. Epub 2018 Nov 9.

PMID:
30419272
5.

Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine.

Bymaster FP, Chao P, Schulze H, Tran PV, Marshall RD.

Drug Metab Lett. 2013 Mar;7(1):23-33.

PMID:
23826879
6.

Reinforcing and neural activating effects of norharmane, a non-nicotine tobacco constituent, alone and in combination with nicotine.

Arnold MM, Loughlin SE, Belluzzi JD, Leslie FM.

Neuropharmacology. 2014 Oct;85:293-304. doi: 10.1016/j.neuropharm.2014.05.035. Epub 2014 Jun 5.

PMID:
24907588
7.

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Tran P, Skolnick P, Czobor P, Huang NY, Bradshaw M, McKinney A, Fava M.

J Psychiatr Res. 2012 Jan;46(1):64-71. doi: 10.1016/j.jpsychires.2011.09.003. Epub 2011 Sep 16.

8.

Assessing the effects of chronic sazetidine-A delivery on nicotine self-administration in both male and female rats.

Johnson JE, Slade S, Wells C, Petro A, Sexton H, Rezvani AH, Brown ML, Paige MA, McDowell BE, Xiao Y, Kellar KJ, Levin ED.

Psychopharmacology (Berl). 2012 Jul;222(2):269-76. doi: 10.1007/s00213-012-2642-z.

9.

Increased nicotine self-administration following prenatal exposure in female rats.

Levin ED, Lawrence S, Petro A, Horton K, Seidler FJ, Slotkin TA.

Pharmacol Biochem Behav. 2006 Nov;85(3):669-74. Epub 2006 Dec 28.

10.

Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder.

Xue W, Wang P, Tu G, Yang F, Zheng G, Li X, Li X, Chen Y, Yao X, Zhu F.

Phys Chem Chem Phys. 2018 Feb 28;20(9):6606-6616. doi: 10.1039/c7cp07869b.

PMID:
29451287
11.

Increased self-efficacy to quit and perceived control over withdrawal symptoms predict smoking cessation following nicotine dependence treatment.

Schnoll RA, Martinez E, Tatum KL, Glass M, Bernath A, Ferris D, Reynolds P.

Addict Behav. 2011 Jan-Feb;36(1-2):144-7. doi: 10.1016/j.addbeh.2010.08.024. Epub 2010 Sep 24.

12.

A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch.

Berlin I, Hunneyball IM, Greiling D, Jones SP, Fuder H, Stahl HD.

Psychopharmacology (Berl). 2012 Sep;223(1):89-98. doi: 10.1007/s00213-012-2692-2. Epub 2012 Mar 27.

PMID:
22451094
13.

Dextromethorphan interactions with histaminergic and serotonergic treatments to reduce nicotine self-administration in rats.

Briggs SA, Hall BJ, Wells C, Slade S, Jaskowski P, Morrison M, Rezvani AH, Rose JE, Levin ED.

Pharmacol Biochem Behav. 2016 Mar;142:1-7. doi: 10.1016/j.pbb.2015.12.004. Epub 2015 Dec 15.

14.

Bupropion-varenicline interactions and nicotine self-administration behavior in rats.

Hall BJ, Slade S, Wells C, Rose JE, Levin ED.

Pharmacol Biochem Behav. 2015 Mar;130:84-9. doi: 10.1016/j.pbb.2015.01.009. Epub 2015 Jan 20.

15.

Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats.

Miller LL, Leitl MD, Banks ML, Blough BE, Negus SS.

Pain. 2015 Jan;156(1):175-84. doi: 10.1016/j.pain.0000000000000018.

16.

Mecamylamine (a nicotine antagonist) for smoking cessation.

Lancaster T, Stead LF.

Cochrane Database Syst Rev. 2000;(2):CD001009. Review.

PMID:
10796584
17.

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation.

Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J.

Cochrane Database Syst Rev. 2019 Apr 18;4:CD013308. doi: 10.1002/14651858.CD013308.

PMID:
30997928
18.
19.

Nicotine replacement therapy for smoking cessation.

Silagy C, Mant D, Fowler G, Lancaster T.

Cochrane Database Syst Rev. 2000;(2):CD000146. Review. Update in: Cochrane Database Syst Rev. 2000;(3):CD000146.

PMID:
10796494
20.

A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation.

Becker KM, Rose JE, Albino AP.

Nicotine Tob Res. 2008 Jul;10(7):1139-48. doi: 10.1080/14622200802123294.

PMID:
18629723

Supplemental Content

Support Center